Last reviewed · How we verify

NCT06676501: ET-Bi-MRgFUS

A Study to Evaluate the Safety and Efficacy of Staged Bilateral Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for the Treatment of Essential Tremor

ENROLLING BY INVITATION NA Last updated 6 November 2024
What this trial tests

NA trial testing ExAblate in Essential Tremor in 20 participants. Enrolling by invitation.

Timeline
26 September 2024
Primary endpoint
1 June 2025
1 November 2026

Quick facts

Lead sponsorChinese PLA General Hospital
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date26 September 2024
Primary completion1 June 2025
Estimated completion1 November 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Chinese PLA General Hospital

Who can join

22 and older, any sex, with Essential Tremor or Essential Tremor, Movement Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this prospective, single-arm, open-label study is to asses the safety and efficacy of the staged bilateral thalamotomy using transcranial magnetic resonance guided focused ultrasound system ExAblate 4000, InSightec Ltd.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ExAblate

Trials testing the same drug.

Other recruiting trials for Essential Tremor

Currently open trials in the same condition.

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06676501.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing